Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

计划入组 17 人 · 首次发布于 2016 年 10 月 13 日

Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers

计划入组 10 人 · 首次发布于 2010 年 3 月 11 日

Psilocybin Administration With 5-HT1a Blockade

计划入组 18 人 · 首次发布于 2026 年 5 月 4 日

5-HT1B/D antagonist (SB)

Naratriptan

C₁₇H₂₅N₃O₂S

Almotriptan(Axert)

C₁₇H₂₅N₃O₂S

Center 5

United States

Hangzhou MTR Line 5 Corporation Limited

China

INVESCO LDRRITE US 0-5 YR CO BD IDX CAD UNITS

Akums Launches World's First Lasmiditan Dispersible Tablets for Acute Migraine Treatment

FDA Accepts Axsome's NDA Resubmission for AXS-07 in Acute Migraine Treatment

Enveric Biosciences Engages IP Firm to Defend Patent Claims Related to AbbVie's $1.2 Billion Bretisilocin Acquisition